PNTG Stock Forecast & Price Target

Pennant Gr is benefiting from strong operating momentum, with second-quarter results ahead of Street expectations, raised full-year guidance, and 2026 revenue, adjusted EBITDA, and EPS now guided to $1,171.1MM-$1,190.1MM, $94.4MM-$98.0MM, and $1.34-$1.41, respectively. Its core home health and hospice business is showing resilient demand and margin leverage, as same-store Medicare home health admissions rose 13.6% year over year, hospice ADC grew 10.8%, and HH&H margins improved 70 bps despite wage pressure and prior reimbursement cuts. The outlook is further supported by ahead-of-schedule integration of former UNH/AMED assets, improving clinical quality metrics, and a more favorable reimbursement backdrop, while senior living also added growth with 81.6% occupancy and 5.5% same-store RevPOR growth.

Pennant Gr is vulnerable to a downside case where integration headwinds in transitioning assets force management to pause incremental M&A, undermining the growth strategy that has supported its expansion. Home Health and Hospice, the majority of revenue, face plateauing topline momentum, labor pressure, and margin contraction, while FY27E EBITDAR could run 5% below estimate, compressing valuation to 10.7x or 8.0x. The company also carries elevated exposure to Medicare-funded reimbursement risk, senior housing supply pressure, and compliance challenges across a large multi-state workforce, all of which could impair occupancy, execution, and profitability.